TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12394229
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose solution (control group)
Study: 2310448
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of bupivacaine (100 mg, 40 mL of 0.25%)
Study: 2310448
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of saline
Study: 2310448
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of bupivacaine at the portal sites
Study: 2310448
Drug: Both intraarticular
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intraarticular and subcutaneous injection of bupivacaine
Study: 26284906
Drug: C. militaris
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. militaris (1.5 g/day for 4 weeks)
Study: 26284906
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules filled with microcrystalline cellulose and lactose)
Study: 25451608
Drug: Salmonella typhi
Normalized name: Salmonella Typhi Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmonella typhi vaccine
Study: 18223378
Drug: Standard infant
Normalized name: Standard infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard infant formula supplemented with IGF‐1 (10 microg/100 mL of formula)
Study: 16611656
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care (IC; n = 65; age mean+/‐sd 70+/‐9 yrs; FEV(1) 1.1+/‐0.5 L, 43% predicted)
Study: 16611656
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC; n = 90; age 72+/‐9 yrs; FEV(1) 1.1+/‐0.05 L, 41% pred)
Study: 14571611
Drug: Integrative medical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative medical treatment (IMT) with serial Chinese recipes and western medicine
Study: 12585170
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone (control group)
Study: 11028724
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of bupivacaine/fentanyl (EPI group)
Study: 11028724
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic regimen (intramuscular oxycodone, OPI group)
Study: 9343116
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tolcapone tid
Study: 9343116
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tolcapone tid
Study: 8363071
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of 75 micrograms clonidine
Study: 29070768
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy for 24 weeks
Study: 23278870
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA) combined with low-fluence 1064-nm QSNY laser treatment for melasma, taken for 8 weeks.
Study: 23278870
Drug: Low-fluence 1064-nm
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-fluence 1064-nm QSNY laser treatment for melasma (control group).
Study: 20977582
Drug: High-protein meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein meal (860 kJ, 21 g protein, 0.7 g fat, 29.6 g carbohydrate) ingested immediately prior to resistance training (RT)
Study: 20977582
Drug: High-protein meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein meal (860 kJ, 21 g protein, 0.7 g fat, 29.6 g carbohydrate) ingested at least 2 hours following resistance training (RT)
Study: 18642658
Drug: Control (2HRZ/4HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2HRZ/4HR chemotherapy)
Study: 16896999
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy (ACE inhibitor)
Study: 12510038
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of intravenous natalizumab per kilogram
Study: 12510038
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of intravenous natalizumab per kilogram
Study: 10939785
Drug: Perindopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (ACE inhibitor) and indapamide (diuretic) for those without contraindications
Study: 8865870
Drug: Computerized urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized urea kinetic model (PACK‐PD) for calculating prescription parameters for peritoneal urea clearance (pKpt/V).
Study: 6727656
Drug: h‐PRL induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: h‐PRL induced by oral priming with 10 mg metoclopramide (MET)
Study: 6727656
Drug: normoprolactinemia (n‐PRL)
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: normoprolactinemia (n‐PRL) after oral priming with placebo
Study: 30876432
Drug: rIPostC (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIPostC (twice daily exposure to four cycles of 5-min cuff inflation to > 20 mmHg above systolic blood pressure)
Study: 30876432
Drug: Sham conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham conditioning (twice daily exposure to four cycles of 5-min cuff inflation to 50 mmHg)
Study: 27645352
Drug: GNbAC1 6
Normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNbAC1 6 mg/kg
Study: 27645352
Drug: GNbAC1 12
Normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNbAC1 12 mg/kg
Study: 27645352
Drug: GNbAC1 18
Normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNbAC1 18 mg/kg
Study: 20138255
Drug: D1 receptor
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 receptor antagonist [(11)C]SCH23390
Study: 17912528
Drug: Covered urethroplasty
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covered urethroplasty (CU group) with a vascularized subcutaneous ventral flap
Study: 11483905
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cisapride
Study: 1412112
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 50 mg every six hours for 48 hours followed by oral prednisone (20 mg/day)
Study: 1412112
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 100 mg every six hours for 48 hours followed by oral prednisone (40 mg/day)
Study: 1412112
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 500 mg every six hours for 48 hours followed by oral prednisone (60 mg/day)
Study: 1412112
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (low, medium, high dose hydrocortisone)
Study: 3998832
Drug: Augmented fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented fluid replacement (2800 +/- 400 ml)
Study: 3998832
Drug: Routine fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid administration (1220 +/- 102 ml)
Study: 31262657
Drug: Dose-escalation strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation strategy (starting dose 80 mg/day orally with weekly escalation to 160 mg/day)
Study: 31262657
Drug: Standard-dose strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose strategy (160 mg/day orally for 21 days of a 28-day cycle)
Study: 31262657
Drug: Dose-escalation strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation strategy
Study: 31262657
Drug: Standard-dose strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose strategy
Study: 30907301
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (clopidogrel and aspirin)
Study: 29635252
Drug: Major allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major allele G at rs12041331, minor allele G at rs2644592, minor allele C at rs11264580, minor allele C at rs11249454
Study: 22869515
Drug: Shockwave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shockwave therapy (SW)
Study: 20231521
Drug: Palosuran 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palosuran 125 mg BID for 4 weeks
Study: 19002405
Drug: Molsidomine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (16 mg once daily)
Study: 9949387
Drug: Liposuction combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposuction combined with Controlled Compression Therapy (CCT)
Study: 10987239
Drug: Controlled Compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled Compression Therapy (CCT) alone
Study: 8158702
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (non-XRT group)
Study: 2893864
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of TOPV (600,000 TCID50 of type 3)
Study: 2893864
Drug: Monovalent vaccine
Normalized name: rotavirus, live, monovalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccine (300,000 TCID50 of type 3)
Study: 27816804
Drug: MDCO‐216 (apoA-IMilano/POPC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO‐216 (apoA-IMilano/POPC) at doses of 5, 10, 20, 30, or 40 mg/kg infused over 2 hours
Study: 22486209
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of water
Study: 23690341
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of water
Study: 17161256
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg once-daily for 6 months
Study: 9373422
Drug: Monitored light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitored light intravenous sedation
Study: 9373422
Drug: Unmonitored deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmonitored deep intravenous sedation
Study: 28954299
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of HPV16/18 vaccine
Study: 28954299
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV16/18 vaccine (0/6 months)
Study: 28954299
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV16/18 vaccine (0/1 month)
Study: 28954299
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of HPV16/18 vaccine
Study: 27168167
Drug: Intramuscular hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hydroxyprogesterone caproate (250 mg weekly)
Study: 27168167
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone suppository (100 mg daily)
Study: 25041740
Drug: LL-37 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LL-37 (0.5 mg/mL)
Study: 25041740
Drug: LL-37 (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LL-37 (1.6 mg/mL)
Study: 25041740
Drug: LL-37 (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LL-37 (3.2 mg/mL)
Study: 21933833
Drug: Valsartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (20 mg daily) for 30 days
Study: 20698232
Drug: Perioperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative oral nutrition with branched chain amino acids (BCAA) - 11 patients, received BCAA supplement twice daily plus a usual diet for 14 days before operation and on days 1 to 7 after operation.
Study: 19563665
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam
Study: 18166545
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam (for children without malaria)
Study: 18166545
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam (for children without malaria)
Study: 16023510
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam and Rectal diazepam
Study: 8743403
Drug: Cefadroxil 250
Normalized name: cefadroxil 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 250 mg
Study: 4005394
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg
Study: 475366
Drug: Cefadroxil 1000
Normalized name: cefadroxil 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1000 mg
Study: 8743403
Drug: Cephalexin 250
Normalized name: cephalexin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 250 mg
Study: 4005394
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg
Study: 8743403
Drug: Cephalexin 1000
Normalized name: cephalexin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1000 mg
Study: 1672589
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of family psychoeducation and social skills training
Study: 28874242
Drug: micro-dose rhEpo
Approvals — FDA: no, EMA: no, PMDA: no
Description: micro-dose rhEpo (20 IU/kg/week)
Study: 28874242
Drug: low-dose rhEpo
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose rhEpo (60 IU/kg/week)
Study: 23986461
Drug: Combined methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined methylphenidate therapy and EEG feedback training
Study: 23986461
Drug: Methylphenidate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate therapy and non‐feedback attention training (Control)
Study: 21733603
Drug: 0.18 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 g/kg/day citrulline for 7 days
Study: 17178941
Drug: Meniett device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meniett device therapy
Study: 12658071
Drug: Ecopipam (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam (0, 30 or 100 mg)
Study: 12658071
Drug: Nicotine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2 mg/70 kg)
Study: 11091263
Drug: Educators' method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educators' method (monthly calendar returns)
Study: 1451342
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) administered subcutaneously once weekly, dosage titrated to maintain hematocrit at 35-38%.
Study: 6391074
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g zinc sulphate 3 times daily
Study: 22986112
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin analog (latanoprost 0.005%)
Study: 21620591
Drug: Behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatments for cannabis use disorders
Study: 19220066
Drug: Cyclobenzaprine extended-release
Normalized name: cyclobenzaprine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine extended-release (CER) 30 mg
Study: 19220066
Drug: Cyclobenzaprine immediate-release
Normalized name: cyclobenzaprine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine immediate-release (CIR) 10 mg administered every 8 hours for a total of three doses
Study: 14763665
Drug: Self-pressure (SP)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-pressure (SP) group - antihypertensive therapy based on home blood pressure measurements.
Study: 14763665
Drug: Office pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office pressure (OP) group - antihypertensive therapy based on blood pressure measured in the outpatient clinic.
Study: 14763665
Drug: Medication compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication compliance recorded in random subgroups of SP and OP groups using MEMS V TrackCaps.
Study: 10866006
Drug: Atropine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1.0 mg intravenously after 5 min of steady state
Study: 10866006
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride administered after 10 min (group B)
Study: 9200357
Drug: Infasurf (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infasurf (n = 303, treatment arm)
Study: 1412608
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g IVPB q 12 h
Study: 1412608
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 mg/kg IVPB q 8 h plus mezlocillin 4 g IVPB q 6 h
Study: 3929314
Drug: Deprenyl 10
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 10 mg/day
Study: 3929314
Drug: Deprenyl 30
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 30 mg/day
Study: 3929314
Drug: Deprenyl 60
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 60 mg/day
Study: 19608168
Drug: Vaginal gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel (daily)
Study: 19608168
Drug: Endometrin treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin treatments (two times and three times a day)
Study: 18361737
Drug: Normal-calorie CBJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-calorie CBJ (280 Cal/480 mL)
Study: 18361737
Drug: Low-calorie CBJ
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie CBJ (38 Cal/480 mL)
Study: 18361737
Drug: Water (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (480 mL)
Study: 14623542
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg daily and celecoxib 400 mg twice daily (group A)
Study: 14623542
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg daily (group B)
Study: 14623542
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily (group C)
Study: 8836901
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 10 mg.kg‐1.day‐1 and prednisolone 10 mg
Study: 8836901
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 10 mg.kg‐1.day‐1 and placebo
Study: 6491914
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1 mg bumetanide
Study: 6491914
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 1 mg bumetanide
Study: 6491914
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution administration of 1 mg bumetanide
Study: 6491914
Drug: Tablet administration
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administration of 1 mg bumetanide
Study: 6491914
Drug: All administration
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All administration routes
Study: 6491914
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and oral preparations
Study: 25293818
Drug: 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/kg BW (standard dose or SD group)
Study: 25293818
Drug: 0.05 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mmol/kg BW (half dose or HD group)
Study: 28255768
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 mcg)
Study: 17611821
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (100 mg per day) along with ferrous sulphate (200 mg per day) and folic acid (5 mg per day) for 3 months
Study: 17611821
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with ferrous sulphate (200 mg per day) and folic acid (5 mg per day) for 3 months